Daxor (DXR) Competitors $8.06 -0.13 (-1.59%) As of 03/26/2025 03:44 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DXR vs. LNSR, AVR, CATX, PDEX, OBIO, SGHT, STIM, INFU, KRMD, and ZJYLShould you be buying Daxor stock or one of its competitors? The main competitors of Daxor include LENSAR (LNSR), Anteris Technologies Global (AVR), Perspective Therapeutics (CATX), Pro-Dex (PDEX), Orchestra BioMed (OBIO), Sight Sciences (SGHT), Neuronetics (STIM), InfuSystem (INFU), KORU Medical Systems (KRMD), and Jin Medical International (ZJYL). These companies are all part of the "medical equipment" industry. Daxor vs. LENSAR Anteris Technologies Global Perspective Therapeutics Pro-Dex Orchestra BioMed Sight Sciences Neuronetics InfuSystem KORU Medical Systems Jin Medical International Daxor (NASDAQ:DXR) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, community ranking, earnings, media sentiment, dividends, risk and analyst recommendations. Which has better valuation & earnings, DXR or LNSR? Daxor has higher earnings, but lower revenue than LENSAR. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDaxor$2.13M18.30N/AN/AN/ALENSAR$53.49M3.12-$14.38M-$2.72-5.20 Is DXR or LNSR more profitable? Daxor has a net margin of 0.00% compared to LENSAR's net margin of -34.03%. Daxor's return on equity of 0.00% beat LENSAR's return on equity.Company Net Margins Return on Equity Return on Assets DaxorN/A N/A N/A LENSAR -34.03%-49.02%-21.12% Do analysts rate DXR or LNSR? Daxor currently has a consensus target price of $25.00, indicating a potential upside of 210.17%. LENSAR has a consensus target price of $15.00, indicating a potential upside of 6.08%. Given Daxor's stronger consensus rating and higher probable upside, research analysts plainly believe Daxor is more favorable than LENSAR.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daxor 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00LENSAR 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community prefer DXR or LNSR? LENSAR received 4 more outperform votes than Daxor when rated by MarketBeat users. However, 100.00% of users gave Daxor an outperform vote while only 40.00% of users gave LENSAR an outperform vote. CompanyUnderperformOutperformDaxorOutperform Votes2100.00% Underperform VotesNo VotesLENSAROutperform Votes640.00% Underperform Votes960.00% Do institutionals & insiders hold more shares of DXR or LNSR? 1.3% of Daxor shares are owned by institutional investors. Comparatively, 40.2% of LENSAR shares are owned by institutional investors. 59.0% of Daxor shares are owned by company insiders. Comparatively, 38.5% of LENSAR shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer DXR or LNSR? In the previous week, LENSAR had 11 more articles in the media than Daxor. MarketBeat recorded 13 mentions for LENSAR and 2 mentions for Daxor. Daxor's average media sentiment score of 1.44 beat LENSAR's score of 0.42 indicating that Daxor is being referred to more favorably in the media. Company Overall Sentiment Daxor Positive LENSAR Neutral Which has more volatility & risk, DXR or LNSR? Daxor has a beta of -0.53, meaning that its share price is 153% less volatile than the S&P 500. Comparatively, LENSAR has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. SummaryDaxor beats LENSAR on 10 of the 15 factors compared between the two stocks. Remove Ads Get Daxor News Delivered to You Automatically Sign up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DXR vs. The Competition Export to ExcelMetricDaxorSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.99M$4.42B$5.63B$8.15BDividend YieldN/A32.62%4.55%4.00%P/E RatioN/A28.7924.4919.08Price / Sales18.3049.55385.2994.58Price / CashN/A51.0838.1634.64Price / BookN/A6.166.954.36Net IncomeN/A$67.64M$3.20B$247.23M7 Day Performance-2.54%-0.66%-2.42%-0.61%1 Month Performance4.13%-2.43%2.18%-5.12%1 Year Performance-6.82%19.33%12.85%3.60% Daxor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DXRDaxor3.9597 of 5 stars$8.06-1.6%$25.00+210.2%-6.8%$38.99M$2.13M0.0037Positive NewsGap UpLNSRLENSAR0.7686 of 5 stars$14.13-0.8%$15.00+6.2%+299.4%$166.56M$53.49M-9.68110Analyst ForecastHigh Trading VolumeAVRAnteris Technologies GlobalN/A$4.62-9.8%$16.50+257.1%N/A$166.43M$2.71M0.00138News CoverageGap UpCATXPerspective Therapeutics2.9115 of 5 stars$2.45-3.0%$14.56+495.3%N/A$165.25M$1.43M0.0070Analyst ForecastPDEXPro-Dex1.3494 of 5 stars$50.38+0.8%$52.00+3.2%+186.9%$164.29M$61.00M25.06140Insider TradeShort Interest ↑OBIOOrchestra BioMed1.7115 of 5 stars$4.29-6.2%$15.40+259.4%-16.7%$162.89M$2.65M-2.664SGHTSight Sciences3.1872 of 5 stars$2.83-8.0%$3.83+35.7%-46.9%$145.02M$79.87M-2.77210Short Interest ↑STIMNeuronetics2.1175 of 5 stars$4.46-4.6%$5.50+23.5%-14.3%$136.45M$74.89M-3.66180Short Interest ↑INFUInfuSystem1.9044 of 5 stars$6.12+0.7%$13.00+112.6%N/A$128.47M$134.86M101.93410KRMDKORU Medical Systems2.7484 of 5 stars$2.76-2.1%$4.70+70.3%+24.7%$126.61M$33.65M-11.0280ZJYLJin Medical InternationalN/A$0.69-5.4%N/A-79.7%$107.24M$23.50M0.00245Gap Up Remove Ads Related Companies and Tools Related Companies LENSAR Alternatives Anteris Technologies Global Alternatives Perspective Therapeutics Alternatives Pro-Dex Alternatives Orchestra BioMed Alternatives Sight Sciences Alternatives Neuronetics Alternatives InfuSystem Alternatives KORU Medical Systems Alternatives Jin Medical International Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DXR) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daxor Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Daxor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
